PET/CT TUMOR IMAGING

DATE:  4/28/2006

PROCEDURE:  Following IV injection of 18-fluoro-2-deoxyglucose (FDG) and a standard uptake period, the patient was imaged on a CTI PET/CT (CTI Reveal) scanner.  After a CT image was acquired for photon attenuation correction, multiple three-minute bed position acquisitions were obtained along the length of the patient's body from the mid thigh to the base of the skull.

FDG DOSE: [15] mCi

CORRELATION: None

COMPARISON: None

CLINICAL HISTORY: The patient is a [...]-year-old [fe]male with a history of [...]. This examination is being done for re-staging purposes.

FINDINGS: 

Normal metabolic activity is noted within the head and neck musculature, bilateral lung fields, liver, spleen, remainder of the gastrointestinal tract, kidneys, and urinary bladder.

No focus of abnormal metabolic activity is seen in the cervical, supraclavicular, mediastinal, axillary, retroperitoneal or inguinal nodal regions.

Normal metabolic activity is seen throughout the remainder of the cortical structures bilateral, basal ganglia, thalami and the cerebellum. The interhemispheric, interthalamic, intercaudate and intersulcal distances are within normal limits.

CONCLUSIONS:  

1. PET CT scan without evidence of hypermetabolic malignant disease.

2. No focus of abnormal metabolic activity is seen to suggest tumor recurrence.

3. A separate dedicated CT report will be generated by the Radiology department.

4. A CT scan was performed, but was used only for attenuation correction and anatomic correlation.  If a comprehensive diagnostic CT is required, the Radiology Department should be consulted for an adjunct CT study. 
 
I, [...], M.D., Ph.D., have reviewed this Nuclear Medicine study personally, and am in full agreement with the findings of the report presented here.